Tema Cardiovascular and Metabolic ETF
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
A fund that holds many companies, so profit, growth, price and debt are not measured for it as for one company.
AI analysis
An AI analyst reads Tema Cardiovascular and Metabolic ETF's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Tema Cardiovascular and Metabolic ETF
Is Tema Cardiovascular and Metabolic ETF a good stock to buy?
A fund that holds many companies, so profit, growth, price and debt are not measured for it as for one company. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tema Cardiovascular and Metabolic ETF AI analysis
What does Tema Cardiovascular and Metabolic ETF do?
The Tema Heart & Health ETF (HRTS) seeks to invest in companies that potentially stand to benefit from further advances in biotechnology and healthcare, specifically companies involved in cardiology, metabolic diseases and weight loss therapies. It is in Asset Management.
How has Tema Cardiovascular and Metabolic ETF stock done over the past year?
Up 14.3% over the past twelve months, to $39.24. It traded between $32.59 and $39.84, close to its high.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.